Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Hall

Nurse Practitioner Fleming Island, FL Nurse Practitioner

NPI 1548771678 CMS profile 11115828

2310 Village Square Pkwy Ste 202, Fleming Island, FL 32003

Open in the dashboard

General payments

$14,557

814 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Hall of Fleming Island, FL is reported in the CMS Open Payments database as having received $14,557 across 814 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,800 193
2024 General $4,614 233
2023 General $2,886 175
2022 General $1,018 56
2021 General $2,239 157

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Hall
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amanda Hall were reported at $3,800. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amanda Hall Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,239 $135 $40–$426 $132
2022 $1,018 $152 $48–$470 $149
2023 $2,886 $166 $54–$529 $160
2024 $4,614 $173 $55–$556 $164
2025 $3,800 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,717 232 payments
  2. Novartis Pharmaceuticals Corporation $1,150 61 payments
  3. SK Life Science, Inc. $924 38 payments
  4. Pfizer Inc. $838 53 payments
  5. Lilly USA, LLC $638 32 payments
  6. Eisai Inc. $608 28 payments
  7. Biogen, Inc. $574 35 payments
  8. UCB, Inc. $522 16 payments
  9. EMD Serono, Inc. $502 28 payments
  10. Lundbeck LLC $479 28 payments
  11. Other $5,605 263 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,366 810 payments
  2. Education $191 4 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,631 156 payments
  2. QULIPTA $1,222 116 payments
  3. KESIMPTA $925 47 payments
  4. NURTEC ODT $627 41 payments
  5. ZAVZPRET $611 40 payments
  6. VRAYLAR $453 22 payments
  7. VALTOCO $447 21 payments
  8. Leqembi $401 18 payments
  9. TYSABRI $401 26 payments
  10. HYQVIA $377 14 payments
  11. Other $8,618 434 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

202

Median for Nurse Practitioner: 389

Drug cost

$103,475

Median for Nurse Practitioner: $21,885

Branded share of claims

36.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 27 $44,357
Qulipta Atogepant Brand 22 $28,792
Botox Onabotulinumtoxina Brand 13 $16,839
Zavzpret Zavegepant Hcl Brand 11 $11,570
Gabapentin Generic 51 $689
Rasagiline Mesylate Generic 11 $496
Duloxetine Hcl Generic 16 $312
Primidone Generic 20 $237
Donepezil Hcl Generic 31 $182

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
$549 — —
VRAYLAR
$305 — —
UBRELVY
$255 27 —
PURIFIED CORTROPHIN GEL
$253 — —
QULIPTA
$242 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

814 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record